Taiho Pharmaceutical Secures Exclusive Licensing Rights for Casdatifan from Arcus Biosciences in Japan and Select Asian Territories

Shots:Taiho Pharmaceutical has exercised its option to develop & commercialize casdatifan, pending approval in Japan & other Asian regions (excl. Greater China) under Taiho & Arcus’ 2017 option & license agreementAs per the deal, Arcus will receive an option exercise payment & clinical, regulatory, plus commercial milestone payments, with net sales-based royalties. Although…

ByRidhi RastogiOctober 22, 2025

INSIGHTS+

Insights+: The US FDA New Drug Approvals in August 2023

Shots:The US FDA approved 10 NDAs and 3 BLA in August 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 89 novel products in 2023In August 2023, the major highlights drugs were Zurzuvae (zuranolone) approval for women with postpartum depression and Veopoz (pozelimab-bbfg) for children…

BySenior EditorSeptember 20, 2023

Taiho Pharmaceutical Secures Exclusive Licensing Rights for Casdatifan from Arcus Biosciences in Japan and Select Asian Territories

Contact US

OUR INFORMATION

FOLLOW US